ESR1 and breast carcinoma: This finding is supported by the observation that miR-342 is highly expressed in ER-positive tumors, in particular in the luminal molecular subclass of breast cancers [13], [14] characterized by better prognosis, and that its expression is directly correlated with the expression levels of the estrogen receptor [14], [32], [33].